Pfizer, BioNTech Stock Price Surge After FDA Approves Its COVID Vaccine

The consensus one-year price target reflects a premium of 14% above the biotech’s current share price. Pfizer (PFE) is working with German partner BioNTech on a Covid-19 vaccine. The company is likely to have efficacy data from late-stage trials available shortly. The company could supply about 40 million doses in the United States in 2020 if the data is positive and regulators approve the vaccine. Novavax’s vaccine could also emerge popular in low and middle-income markets.

So Afrigen’s work has the potential to massively expand global access to vaccines. All three companies said that their updated vaccines produced robust immune responses against the now-dominant EG.5, or “Eris,” variant in trials. That omicron strain is closely related to XBB.1.5 and oem parts meaning accounted for 21.5% of all U.S. cases as of Sept. 2, according to the CDC. People recently vaccinated should wait two months before getting an updated vaccine, according to the CDC’s Wallace. Spacing out shots will allow people to maximize the protection they get from each shot.

Will the new Covid shots be free?

The agency’s website outlines more specific guidelines for staying up to date on Covid vaccines, which differ depending on age group and risk level. But the recent uptick is raising concerns about how much traction Covid will gain in the coming fall and winter months, when respiratory viruses typically spread at higher levels and people spend more time indoors. The COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. The CDC has previously indicated that BA.2.86 may be more capable of causing infection in people who previously had COVID or were vaccinated with previous shots. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.

• The uptick in coronavirus cases could push more people to get vaccinated — and that may encourage healthcare providers to increase vaccine orders.
• Around 85% of uninsured Americans live within five miles of a location participating in that program, according to Dr. Evelyn Twentyman, a CDC medical officer.
• “We think this is news people will want to hear as they prepare to go out and get their fall boosters,” Moderna head of infectious diseases Jacqueline Miller said in an interview, adding that the data should also help reassure regulators.
• In the European Union, the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) has also received marketing authorization by the European Commission for individuals 6 months of age and older on August 31, 2023.
• The company’s diversified operations across healthcare and its status as a Dividend King position Johnson & Johnson stock as one of the safest stock picks for long-term investors.

The coronavirus clearly isn’t as widespread as it was during the early days of the health crisis. Pharmaceutical companies at the center of the pandemic response have been bulking up their lobbying efforts and significantly contributing to political campaigns. When Insider followed up on December 3, DuRant said she didn’t have anything new to add to her previous statement. Early in the pandemic, some lawmakers condemned people looking to make money off COVID-19-related treatments and defenses.

Exclusive: Rotavirus childhood vaccine shortage hits four African countries

The updated shots will soon be available to eligible people at pharmacies, health clinics and community centers, among other vaccine distribution sites. Those locations will stop offering last year’s bivalent boosters, which are no longer authorized for use in the U.S. In the European Union, the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) has also received marketing authorization by the European Commission for individuals 6 months of age and older on August 31, 2023. Pfizer and BioNTech have submitted data for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine to other regulatory authorities around the world.

It’s actually what your body does all the time.” When the company was created, the thought was they’d be able to use mRNA technology for treatments of a range of diseases, he says. “That’s the whole premise of investing in our mRNA platform,” Mock says. He joined Moderna as CFO in September 2022, coming from PerkinElmer, a life sciences and diagnostics company, where he was also a finance chief.

“The vaccines have been manufactured has been prepositioned in our U.S. distribution hub, awaiting EUA and the start of the fall campaign,” Novavax’s Filip Dubovsky said. Prosper Junior Bakiny has no position in any of the stocks mentioned. The visiting scientists were chemists, biochemists and bioprocessing engineers with deep experience working on vaccines, notes Terblanche.

US FAA gives drone pilots six more months to install remote ID module

So clearly vaccination programs are just getting started based on the larger scheme of things. With bond yields rising and the economy continuing to open up, investors have been rotating out of pandemic winners such as vaccine and work from home names to more cyclical and value stocks. For example, Moderna and Novavax – both viewed as a direct play on Covid-19 vaccines are down by about 28% and 44% respectively from their February highs.

So if a patient has upcoming travel or a large gathering to attend in mid-October, they could plan to get the new shot at the beginning of that month. The U.S. Covid public health emergency ended in May, which means the federal government is shifting vaccine distribution https://1investing.in/ to the private market this fall. People ages 65 years and older may get an additional dose of a new Covid vaccine four or more months after a first dose of an updated shot. The CDC on Tuesday recommended that all Americans ages 6 months and older get the new shots.

Those mRNA vaccines are designed to target a relatively new omicron subvariant called XBB.1.5. The company has an annual influenza vaccine in phase 2/3 trials as well — and the total addressable market for flu vaccines is anticipated to be almost $10 billion in 2030. This all feeds nicely into the organization’s clear goal of bringing a pan-respiratory-virus annual vaccine to market. Novavax wrapped up the final analysis for its seasonal flu vaccine’s pivotal trial in September, and the study’s results were subsequently published in The Lancet Infectious Diseases. The most important takeaway for investors is that NanoFlu did, in fact, achieve statistical significance on the trial’s primary endpoints.

Seeking Alpha author Nathan Aisenstadt reaffirmed his Buy rating on Pfizer (PFE) on Friday, arguing that the recent decline of COVID vaccine sales may have bottomed out with the emergence of the new Omicron variant EG.5.1. “Significant buying opportunity,” “buy while it’s cheap,” and “dead cat bounce” were some of the terms Seeking Alpha analysts used to describe their stocks, none of which are Buy-rated, according to SA’s Quant ratings. These numbers still are significantly lower than Moderna’s and Pfizer’s vaccine sales last year, when the products generated more than $18 billion and $37 billion in sales, respectively. The Centers for Disease Control and Prevention (CDC) has collected data on U.S. cases and hospitalizations since early in the crisis. The most recent numbers show test positivity at more than 14%, the highest since February of last year. And coronavirus hospitalizations climbed more than 18% in the week ended Aug. 19 from the previous week.

It is unclear if RSV boosters would be needed, but considering the two-dose series of GlaxoSmithKline’s (GSK -0.27%) shingles vaccine Shingrix saw $2.4 billion in sales in 2019, this could be a major opportunity for Moderna. The company expects to add $10 billion to $15 billion in annual sales five years after launching new products in oncology, rare, and latent diseases by 2028. This is in addition to the previously announced $8 billion to $15 billion of expected sales from the respiratory franchise (COVID, RSV and flu) in 2027, according to the company. Moderna plans on investing approximately $25 billion in research and development from 2024 through 2028. But analysts aren’t gung ho about the prospects for any of these leaders in the COVID-19 vaccine market. The consensus price targets for all of these stocks are lower than their current share prices.

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

We have identified 15 of the pharmaceutical companies leading the race to find the coronavirus vaccine. Moderna, Pfizer and Novavax have also said that their new shots, which are designed to target a related omicron subvariant called XBB.1.5, should provide protection against Eris. With this context in mind, here is our list of 10 best vaccine stocks to buy now.

In the U.S., Covid-related hospitalizations are up more than 40% off recent lows in June, according to Reuters. Still, hospitalization rates are more than 90% below peak levels during the January 2022 omicron outbreak. Until BioNTech gets “the COVID guidance monkey off its back, this will remain purgatory for most investors,” Jefferies analysts led by Akash Tewari wrote in a Monday note to clients. The stock crashes moved against broader market gains, with the Dow Jones Industrial Average’s 408-point, or 1.2%, rally its strongest since June 2. Malinowski has since placed his stock assets in a qualified blind trust. The New Jersey lawmaker is one of 10 lawmakers who have taken the option to use a qualified blind trust, Insider found.

Nasdaq Futures

“Vaccines remain the primary prevention measure and largest market opportunity,” Morgan Stanley analyst Matthew Harrison wrote in a note dated Oct. 5. “The Covid pills are really a complement to the vaccines,” said Shane Oliver, head of investment strategy at AMP Capital Investors Ltd. in Sydney. They could reduce demand for costlier treatments such as intravenous medicines, he added. Get this delivered to your inbox, and more info about our products and services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

This could make the Novavax vaccine – which can be produced at scale and easily distributed – popular if the pricing is suitably adjusted. Novavax’s vaccine is based on subunits – essentially using a fragment of the virus – and the manufacturing process is apparently more complex compared to the method used in messenger RNA vaccines including Moderna’s. This could potentially make the Novavax vaccine more expensive to manufacture. Based on a supply agreement with the U.S. government, the Novavax vaccine will be priced at about $16 per dose, below the $19.50 for Pfizer’s vaccine and as much as $37 per dose for Moderna’s. The potentially more complex manufacturing process and lower prices could mean that margins might be lower. The vaccine leaders may also lose market share if new inoculations from Sanofi, Novavax Inc. or Valneva SE succeed and if mix-and-match boosting appears to be effective.

• And Vir is actively pursuing vaccines for hepatitis B, the flu, and HIV.
• And, as of last May, a series of “challenge” trials were completed in which hamsters were given the vaccine and then exposed to the coronavirus to show that the Afrigen vaccine was just as effective as Moderna’s in preventing infection.
• Considering this, we think that investors will need to evaluate these companies based on the potential of their future pipelines, rather than just focusing on their Covid vaccines.
• Many of those biotechs on the front lines of the fight against the coronavirus seem to be coming back to life after their shares got hammered over the past year or more.
• Pfizer (PFE) is working with German partner BioNTech on a Covid-19 vaccine.

A third vaccine option is also expected to roll out later this season from Novavax, for Americans as young as 12 years old. That shot will be automatically added to the CDC’s recommendation once the FDA completes its final review of Novavax’s submission. The Biden administration plans to list some locations it knows about with shots in stock on its Vaccines.gov webpage later this week.

We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Novavax announced that it was commencing phase 3 clinical trials for its novel coronavirus vaccine in the U.S. and Mexico last week. For example, prospective volunteers might be concerned that they are given a placebo or that Novavax’s candidate could be less protective or even if their involvement in the trial could impact their ability to take another vaccine.

See our indicative theme of  Covid-19 Vaccine stocks which includes U.S.-listed pharma and biotech companies. The share price of Pfizer’s German partner BioNTech is even cheaper at 5.9 times earnings, despite tripling this year. A tiny Israeli biotech, RedHill Biopharma Ltd., said Oct. 4 its experimental oral therapy showed promise in helping hospitalized patients. The study consisted of only 251 people; weeks earlier RedHill had said the drug failed to show an effect in a broader group of patients.

The CDC said that everyone ages 6 and older should get at least one dose of an updated mRNA vaccine this year, regardless of whether they’ve received any of the original Covid shots. The first doses of the new shots will be available at some pharmacies and other vaccine distribution locations within 48 hours of the CDC’s recommendation, agency staff said Tuesday during a meeting of independent advisors to the CDC. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2023 and in subsequent filings made by BioNTech with the U.S. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof.

However, that isn’t the case in some other parts of the world, and the emergence of new coronavirus variants could fuel demand for vaccines for a long time to come. These questions are difficult to answer because cases of COVID-19 will likely continue to fluctuate. And while that means there are times when Novavax’s sales — and stock price — will jump as cases are going up, it also means that once things cool down, the company won’t perform nearly as well. This isn’t a recipe for delivering consistently solid returns over the long run, so unless Novavax has something else in development, it might not be worth the trouble, at least not for those investors focused on the long game.